Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-306 tarlatamab maintenance after chemoradiotherapy for limited-stage small cell lung cancer
MOH_2024-05-19_013419Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tarlatamab with Placebo (2 arms). Primary endpoint: Progression-free survival. Started May 2024; status: completed.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2024-05-19_013419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-19_013419.